Stock News and Filings Feed


Add 500126
to your dashboard

RXi Pharmaceuticals' (RXII) CEO Dr. Geert Cauwenbergh on Q2 2017 Results - Earnings Call Transcript

2017-08-11 seekingalpha
Good day, ladies and gentlemen and welcome to today’s webcast entitled RXi Pharmaceuticals Second Quarter 2017 Financial Results Conference Call. Today’s call is being recorded.

Celgene Ends Option to Buy Sutro, Gains Rights to I/O Candidates in Revised Collaboration

2017-08-10 genengnews
Celgene has ended its option to acquire Sutro Biopharma in return for gaining full global rights to a second Sutro preclinical program, and outside-U.S. rights to two others in a reworking of the companies’ immuno-oncology collaboration, whose value was not disclosed.

Tracking Kahn Brothers Portfolio - Q2 2017 Update

2017-08-09 seekingalpha
The portfolio continues to be very concentrated with the top five positions accounting for ~43% of the 13F holdings.

Fresenius' (FSNUY) CEO Stephan Sturm on Q2 2017 Results - Earnings Call Transcript

2017-08-02 seekingalpha
Fresenius SE & Co. KGaA ADR (OTCQX:FSNUY) Q2 2017 Results Earnings Conference Call August 1, 2017 8:00 AM ET

Tracking Ken Fisher's Fisher Asset Management Portfolio - Q2 2017 Update

2017-07-24 seekingalpha
Amazon.com, Johnson & Johnson, Apple Inc., Visa Inc., and Alibaba Group Holdings are the largest five individual stock positions.

Merck Limited - Results

2017-07-21 feedproxy.google

PDS Announces Clinical Collaboration with Merck

2017-07-10 londonstockexchange
London, UK - July 10th 2017 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic IP commercialisation group focused on healthcare, announces a new clinical trial collaboration agreement between its portfolio company PDS Biotechnology Corporation ("PDS") and a subsidiary of Merck & Co., Inc. (known as MSD outside the United States and Canada). The agreement will enable PDS to evaluate the combination of its Versamune®-based PDS0101 immunotherapy treatment with Merck & Co.

1
share
Merck says new type of cholesterol drug reduces risks

2017-06-27 sfgate
Merck & Co. said Tuesday that a new type of cholesterol drug reduced heart attacks, deaths and other complications of heart disease in a huge, late-stage study.

Merck Limited - Shareholders meeting

2017-06-22 feedproxy.google

Merck Limited - Trading Window

2017-06-16 feedproxy.google

Merck Limited - Financial Results Updates

2017-05-19 feedproxy.google

1
share
UPDATE 1-Merck says test shows Keytruda improves survival for bladder cancer patients

2017-05-17 reuters
May 17 Pivotal trial results for Merck & Co Inc's immunotherapy drug Keytruda show that it lengthened survival by three months, or nearly 40 percent, for patients with advanced bladder cancer who had stopped responding to chemotherapy.

Tracking Kahn Brothers Portfolio - Q1 2017 Update

2017-05-09 seekingalpha
The portfolio continues to be very concentrated, with the top five positions accounting for ~46% of the 13F holdings.

1
share
R-Biopharm, Merck KGaA Launch Companion Diagnostics Collaboration

2016-03-22 genengnews
R-Biopharm said today it will partner with Merck KGaA to develop companion diagnostics through a collaboration whose value was not disclosed.

Merck Puts Spotlight on Women's Health and Well-being

2016-02-22 prnewswire
DARMSTADT, Germany, February 22, 2016 /PRNewswire/ -- - Merck's Consumer Health business takes the lead in...

La división Consumer Health de Merck pone el punto de mira en la salud y bienestar de las mujeres

2016-02-22 prnewswire
DARMSTADT, Alemania, February 22, 2016 /PRNewswire/ -- - Merck' Consumer Health toma el liderazgo al hacer...

Merck pone la salud y el bienestar de las mujeres en el centro de su atención

2016-02-22 prnewswire
DARMSTADT, Alemania, 22 de febrero de 2016 /PRNewswire/ -- - La división de Merck para la Salud del...

Merck oferece destaque à saúde e ao bem-estar das mulheres

2016-02-22 prnewswire
DARMSTADT, Alemanha, 22 de fevereiro de 2016 /PRNewswire/ -- - A divisão Consumer Health da...

Merck Form SC 13G/A (Acquisition of More Than 5% of Shares)

2016-02-12 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Merck & Co. Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 58933Y105 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of

Merck Form SC 13G/A (Acquisition of More Than 5% of Shares)

2016-02-11 sec.gov
merckandcoinc.htm - Generated by SEC Publisher for SEC Filing   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 1 )*       Name of issuer:  Merck & Co Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  58933Y105     Date of Event Which Requires Filing of this Statement: December 31, 2015   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule 13d

Merck Form SC 13G/A (Acquisition of More Than 5% of Shares)

2016-02-11 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) MERCK & CO INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 58933Y105 -------------------------------------------------------- (CUSIP Number) December 31, 2015 -------------------------------------------------------- (Date of Event Which R

Merck Form 4 (Change in Ownership/Insider Trade)

2016-02-11 sec.gov
X0306 4 2016-02-08 0 0001651308 BeiGene, Ltd. BGNE 0000310158 Merck & Co., Inc. 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 0 0 1 0 0000942443 Merck Sharp & Dohme Corp. ONE MERCK DRIVE WHITEHOUSE STATION NJ 08889 0 0 1 0 0001665244 Merck Sharp & Dohme Research GmbH WEYSTRASSE 20 LUCERNE 6 V8 CH-6000 SWITZERLAND 0 0 1 0 Ordinary Shares 2016-02-08 4 C 0 18518519 A 18518519 I Via wholly owned subsidiary, MSDRG Ordinary Shares 2016-02-08 4 C 0 5128205 A 5128205 I Via wholly owned subsidiary, MSDRG

1
share
Tracking Kahn Brothers Portfolio - Q4 2015 Update

2016-02-09 seekingalpha
Kahn Brothers Group's US long portfolio increased ~4% from $540M to $560M this quarter. Small stakes in VOXX International and GlaxoSmithKline were increased si

MERCK Form EX-24.1

2016-02-05 sec.gov
Exhibit 24.1   LIMITED POWER OF ATTORNEY   The undersigned hereby constitutes and appoints Katie Fedosz with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:   (1)                                 execute for and on behalf of the undersigned, in the undersigned’s capacity as officer and/or director of Merck Sharp & Dohme Research GmbH (the “Company”), from time to time the following U.

MERCK Form 3 (Change in Ownership/Insider Trade)

2016-02-05 sec.gov
X0206 3 2016-02-02 0 0001651308 BeiGene, Ltd. BGNE 0000310158 Merck & Co., Inc. 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 0 0 1 0 0000942443 Merck Sharp & Dohme Corp. ONE MERCK DRIVE WHITEHOUSE STATION NJ 08889 0 0 1 0 0001665244 Merck Sharp & Dohme Research GmbH WEYSTRASSE 20 LUCERNE 6 V8 CH-6000 SWITZERLAND 0 0 1 0 Series A Preferred Shares Ordinary Shares 18518519 I See Footnote Series A-2 Preferred Shares Ordinary Shares 5128205 I See Footnote These securities consist of Series A Preferre

Fintel IR - Find the Right Investors for Your Company, Instantly!

Fintel IR combines the comprehensive Fintel ownership database with machine learning to provide advanced tools to make investor outreach fast and easy. Learn more now!